Galectin Therapeutics (GALT) SEC Filings: History & Chart

Galectin Therapeutics Inc.(GALT)

Biotechnology · Norcross, GA

$3.70-0.04 (-0.94%)

Delayed quote: Oct 6, 2026, 12:04 PM EDT

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Norcross, GA

9 employees

galectintherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joel Lewis

View full financials

Form	Filing Date	Accepted	Document
PRE 14A	Oct 2, 2026	Oct 2, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
SC 13D/A	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 23, 2026	Jun 23, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
8-K	May 15, 2026	May 15, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
EFFECT	Apr 10, 2026	Apr 13, 2026	View filing
S-3	Mar 31, 2026	Mar 31, 2026	View filing
8-K	Mar 31, 2026	Mar 31, 2026	View filing
10-K	Mar 31, 2026	Mar 31, 2026	View filing
4	Mar 17, 2026	Mar 17, 2026	View filing
3	Mar 17, 2026	Mar 17, 2026	View filing
8-K	Mar 17, 2026	Mar 17, 2026	View filing
4	Feb 9, 2026	Feb 9, 2026	View filing
4/A	Jan 22, 2026	Jan 22, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing
8-K	Jan 21, 2026	Jan 21, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing
4	Jan 21, 2026	Jan 21, 2026	View filing

SEC Filings

Recent Filings